Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report

RATIONALE: Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain medical conditions related to the tumor lesions may not allow oral administration of TKIs. PATIENT C...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Quentin Dominique, Pautas, Marie, Guilhaume, Marie-Noëlle, Fiteni, Fréderic, Ge, Tony, Girard, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556033/
https://www.ncbi.nlm.nih.gov/pubmed/34713842
http://dx.doi.org/10.1097/MD.0000000000027611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556033/
https://www.ncbi.nlm.nih.gov/pubmed/34713842
http://dx.doi.org/10.1097/MD.0000000000027611

Ejemplares similares